Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Long-term treatment of nocturnal enuresis with desmopressin. A follow-up study.

Literature DB >> 1926658

Long-term treatment of nocturnal enuresis with desmopressin. A follow-up study.

U B Knudsen¹, S Rittig, J P Nørgaard, J B Lundemose, E B Pedersen, J C Djurhuus.

Abstract

Eight patients with monosymptomatic nocturnal enuresis (age 11-24 years) were investigated prior to and after 24 weeks of desmopressin treatment in order to evaluate the impact on the endogenous vasopressin secretion and urinary output. No effect on plasma vasopressin, diurnal urinary volume, and urinary osmolality were found after this long-term treatment. Overall no changes in either body weight, blood pressure, or hematological variables were demonstrated. This supports previous findings that the treatment appears to be well tolerated and free of side effects in longer term.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1991 PMID： 1926658 DOI： 10.1007/bf00305302

Source DB: PubMed Journal: Urol Res ISSN： 0300-5623

8 in total

1. Assessment of the safety of regular DDAVP therapy in primary nocturnal enuresis.

Authors: D A Rew; J S Rundle
Journal: Br J Urol Date: 1989-04

2. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis.

Authors: S Rittig; U B Knudsen; J P Nørgaard; E B Pedersen; J C Djurhuus
Journal: Am J Physiol Date: 1989-04

3. Hormonal and cardiovascular responses to DDAVP in man.

Authors: T D Williams; S L Lightman; M J Leadbeater
Journal: Clin Endocrinol (Oxf) Date: 1986-01 Impact factor: 3.478

4. Diurnal anti-diuretic-hormone levels in enuretics.

Authors: J P Nørgaard; E B Pedersen; J C Djurhuus
Journal: J Urol Date: 1985-11 Impact factor: 7.450

5. Adult enuresis. The role of vasopressin and atrial natriuretic peptide.

Authors: S Rittig; U B Knudsen; M Jønler; J P Nørgaard; E B Pedersen; J C Djurhuus
Journal: Scand J Urol Nephrol Suppl Date: 1989

6. Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension.

Authors: E B Pedersen; H Danielsen; E S Spencer
Journal: Eur J Clin Pharmacol Date: 1984 Impact factor: 2.953

7. Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus.

Authors: P S Sørensen; H Vilhardt; F Gjerris; J Warberg
Journal: Eur J Clin Invest Date: 1984-12 Impact factor: 4.686

8. DDAVP in childhood nocturnal enuresis.

Authors: T Tuvemo
Journal: Acta Paediatr Scand Date: 1978-11

8 in total

5 in total

Long-term treatment of nocturnal enuresis with desmopressin. A follow-up study.

1. Assessment of the safety of regular DDAVP therapy in primary nocturnal enuresis.

2. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis.

3. Hormonal and cardiovascular responses to DDAVP in man.

4. Diurnal anti-diuretic-hormone levels in enuretics.

5. Adult enuresis. The role of vasopressin and atrial natriuretic peptide.

6. Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension.

7. Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus.

8. DDAVP in childhood nocturnal enuresis.

Review 1. Hyponatremia in patients with nocturnal enuresis treated with DDAVP.

Review 2. Cure of nocturnal enuresis: why isn't desmopressin very effective?

3. Hyponatraemia and cerebral convulsion due to short term DDAVP therapy for control of enuresis nocturna.

Review 4. Side effects and complications of treatment with desmopressin for enuresis.

5. Primary nocturnal enuresis and desmopressin treatment: do psychosocial factors affect outcome?